Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Still a Buy?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) gapped up before the market opened on Thursday . The stock had previously closed at $16.14, but opened at $17.11. Generate Biomedicines shares last traded at $16.7630, with a volume of 574,702 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GENB. Weiss Ratings assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, August 11th. They set a “sell (d)” rating for the company. Morgan Stanley increased their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright upped their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Generate Biomedicines currently has an average rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Trading Up 7.0%

The company has a market cap of $2.22 billion and a PE ratio of -10.78. The business has a fifty day moving average price of $15.23.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. Equities analysts expect that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Institutional Investors Weigh In On Generate Biomedicines

Several large investors have recently bought and sold shares of GENB. California State Teachers Retirement System acquired a new stake in Generate Biomedicines in the second quarter worth $96,000. Susquehanna International Group LLP acquired a new position in shares of Generate Biomedicines in the 2nd quarter valued at $196,000. AXQ Capital LP acquired a new position in shares of Generate Biomedicines in the 2nd quarter valued at $218,000. Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines in the 2nd quarter valued at $967,000. Finally, Braidwell LP bought a new stake in shares of Generate Biomedicines in the 2nd quarter valued at $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.